科伦药业：12月23日召开董事会会议

Group 1 - The core point of the article is that Kelun Pharmaceutical (SZ 002422) held its 10th meeting of the 8th Board of Directors on December 23, 2025, to review proposals regarding expected related party transactions for the year 2026 [1] - For the first half of 2025, the revenue composition of Kelun Pharmaceutical was as follows: 89.66% from pharmaceutical manufacturing, 7.01% from research and development projects, and 3.33% from other businesses [1] - As of the time of reporting, the market capitalization of Kelun Pharmaceutical was 49 billion yuan [1]